Tour rider fails doping control
The UCI confirms that a rider at the Tour de France has tested positive in a drug control. No detail
PIC BY TDWSPORT.COM
Just as many of us were still getting over the excitement of the final week of the Tour de France, the International Cycling Union has announced that a rider taking part in the race has failed a dope control test. Neither the identity of the rider nor of the test he has failed has been revealed, and nor will they be until a further B test is carried out on a control sample.
“The adverse analytical finding received this morning relates to the first analysis, and will have to be confirmed either by a counter-analysis required by the rider, or by the fact that the rider renounces to that counter-analysis,” the UCI said in a statement on Tuesday.
“The World Anti-Doping Code and the anti-doping rules of the UCI do not allow the making of the name of the concerned rider public, as well as any other information that may allow identification,” the statement continued.
The test was carried out by France’s national anti-doping laboratory at Chatenay-Malabry, just outside Paris. The UCI- and International Olympic Committee-accredited lab has led the development of tests to discover cases of blood doping, although it is not yet known if blood doping is the alleged offence in this instance.
UCI president Pat McQuaid told AFP there would be no let-up in the battle to stamp down on drug cheats. “From my point of view it’s intolerable and we’re determined to root out this problem and deal with it,” McQuaid said. “At the moment I’m concerned over the A sample result. If the B sample turns out to be positive, I’ll be angry.”
Although this is the first potential case of doping during the Tour, the race was of course initially marred by the ejection of nine riders from the event after they were implicated in the Operacion Puerto blood doping investigation in Spain.